168 related articles for article (PubMed ID: 26747656)
1. Nexplanon® removals in a community sexual and reproductive health service.
Chaudhry F
J Fam Plann Reprod Health Care; 2016 Apr; 42(2):160-1. PubMed ID: 26747656
[No Abstract] [Full Text] [Related]
2. Counselling styles and their effect on subdermal contraceptive implant continuation rates.
Rubenstein J; Rubenstein P; Barter J; Pittrof R
Eur J Contracept Reprod Health Care; 2011 Jun; 16(3):225-8. PubMed ID: 21395387
[TBL] [Abstract][Full Text] [Related]
3. Acceptability of long-acting, progestin-only contraception in Europe: a two-year prospective, non-interventional study.
Short M; Dallay D; Omokanye S; Stauch K; Inki P
Eur J Contracept Reprod Health Care; 2014 Feb; 19(1):29-38. PubMed ID: 24289528
[TBL] [Abstract][Full Text] [Related]
4. Nexplanon: the new implant for long-term contraception. A comprehensive descriptive review.
Palomba S; Falbo A; Di Cello A; Materazzo C; Zullo F
Gynecol Endocrinol; 2012 Sep; 28(9):710-21. PubMed ID: 22339096
[TBL] [Abstract][Full Text] [Related]
5. A three-year comparative study of continuation rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or progestogen releasing-intrauterine system.
Weisberg E; Bateson D; McGeechan K; Mohapatra L
Eur J Contracept Reprod Health Care; 2014 Feb; 19(1):5-14. PubMed ID: 24229367
[TBL] [Abstract][Full Text] [Related]
6. Real world data on Nexplanon® procedure-related events: final results from the Nexplanon Observational Risk Assessment study (NORA).
Reed S; Do Minh T; Lange JA; Koro C; Fox M; Heinemann K
Contraception; 2019 Jul; 100(1):31-36. PubMed ID: 30980829
[TBL] [Abstract][Full Text] [Related]
7. Hormone-releasing contraceptive implants: our experience of complex removals using preoperative ultrasound.
Vollans SR; Grainger A; O'Connor P; Limb D
Contraception; 2015 Jul; 92(1):81-3. PubMed ID: 25889152
[TBL] [Abstract][Full Text] [Related]
8. Addressing unmet need for long-acting family planning in Ethiopia: uptake of single-rod progestogen contraceptive implants (Implanon) and characteristics of users.
Asnake M; Henry EG; Tilahun Y; Oliveras E
Int J Gynaecol Obstet; 2013 Nov; 123 Suppl 1():e29-32. PubMed ID: 24035007
[TBL] [Abstract][Full Text] [Related]
9. [Safety profile of etonogestrel contraceptive implant (Nexplanon
Simon C; Agier MS; Béné J; Muller C; Vrignaud L; Marret H; Jonville-Bera AP
J Gynecol Obstet Biol Reprod (Paris); 2016 Nov; 45(9):1074-1082. PubMed ID: 27125380
[TBL] [Abstract][Full Text] [Related]
10. Implant site Nexplanon reaction?
Pedroso C; Martins I; Palma F; Machado AI
BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25953577
[TBL] [Abstract][Full Text] [Related]
11. The effect of immediate postpartum compared to delayed postpartum and interval etonogestrel contraceptive implant insertion on removal rates for bleeding.
Ireland LD; Goyal V; Raker CA; Murray A; Allen RH
Contraception; 2014 Sep; 90(3):253-8. PubMed ID: 24973904
[TBL] [Abstract][Full Text] [Related]
12. Bent implanon®.
Doshi J
J Fam Plann Reprod Health Care; 2011 Apr; 37(2):126. PubMed ID: 21454285
[No Abstract] [Full Text] [Related]
13. Increasing LARC utilization: any woman, any place, any time.
Hathaway M; Torres L; Vollett-Krech J; Wohltjen H
Clin Obstet Gynecol; 2014 Dec; 57(4):718-30. PubMed ID: 25314089
[TBL] [Abstract][Full Text] [Related]
14. Migration of a Subcutaneous Contraceptive Device.
Uwagbai ON; Wittich AC
J Am Osteopath Assoc; 2016 Sep; 116(9):627. PubMed ID: 27571300
[No Abstract] [Full Text] [Related]
15. Incorporating Long-acting Reversible Contraception Into Primary Care: A Training and Practice Innovation.
Pace LE; Dolan BM; Tishler LW; Gooding HC; Bartz D
Womens Health Issues; 2016; 26(2):131-4. PubMed ID: 26542381
[No Abstract] [Full Text] [Related]
16. Bleeding related to etonogestrel subdermal implant in a US population.
Casey PM; Long ME; Marnach ML; Bury JE
Contraception; 2011 May; 83(5):426-30. PubMed ID: 21477684
[TBL] [Abstract][Full Text] [Related]
17. Delayed-type hypersensitivity reaction against Nexplanon®.
Serati M; Bogani G; Kumar S; Cromi A; Ghezzi F
Contraception; 2015 Jan; 91(1):91-2. PubMed ID: 25284356
[TBL] [Abstract][Full Text] [Related]
18. Prevention of unintended pregnancy: a focus on long-acting reversible contraception.
Pickle S; Wu J; Burbank-Schmitt E
Prim Care; 2014 Jun; 41(2):239-60. PubMed ID: 24830607
[TBL] [Abstract][Full Text] [Related]
19. Indications for removal of etonogestrel implant within two years of use in Jos, Nigeria.
Mutihir JT; Nyango DD
East Afr Med J; 2010 Nov; 87(11):461-4. PubMed ID: 23457809
[TBL] [Abstract][Full Text] [Related]
20. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting.
Lakha F; Glasier AF
Contraception; 2006 Oct; 74(4):287-9. PubMed ID: 16982226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
